MedTrace Logo

ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)

NCT00546819 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2017-04-12

Study results available
· View outcomes & findings →

Summary

The purpose of the study was to assess the safety, tolerability, and immunogenicity of ZOSTAVAX™ in patients receiving chronic/maintenance corticosteroids.

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

Zoster Vaccine, Live

A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1

BIOLOGICAL

Comparator: Placebo

A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-08-31
Completion
2010-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546819 on ClinicalTrials.gov